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Neural cell adhesion molecule (NCAM) is expressed by muscle
and involved in muscle-neuron and muscle-muscle cell inter-
actions. The expression in muscle is regulated during myogenesis
and by the state of innervation. In aged muscle, both neurogenic
and myogenic degenerative processes occur. We here report
quantitative and qualitative changes in NCAM protein and
mRNA forms during aging in normal rat skeletal muscle.
Determination of the amount ofNCAM by e.l.i.s.a. showed that
the level decreased from perinatal to adult age, followed by a
considerable increase in 24-month-old rat muscle. Thus NCAM
concentration in aged muscle was sixfold higher than in young
adult muscle. In contrast with previous reports, NCAM poly-
peptides of 200, 145, 125 and 120 kDa were observed by
immunoblotting throughout postnatal development and aging,
the relative proportions of the individual NCAM polypeptides
remaining virtually unchanged at all ages examined. However,
changes in the extent of sialylation ofNCAM were demonstrated.
Even though the relative amounts of the various NCAM
polypeptides were unchanged during aging, distinct changes in
NCAM mRNA classes were observed. Three NCAM mRNA
classes of 6.7, 5.2 and 2.9 kb were present in perinatal and young
adult skeletal muscle, whereas only the 5.2 and 2.9 kb mRNA
classes could be demonstrated in aged muscle. This indicates that
metabolism of the various NCAM polypeptides is individually
regulated during aging. Alternative splicing of NCAM mRNA
in skeletal muscle was studied by Northern blotting using DNA
oligonucleotide probes specifically hybridizing to selected exons
or exon combinations. Exon VASE, which has previously been
shown to be present in both brain and heart NCAM mRNA, was
virtually absent from skeletal muscle at all ages studied. In
contrast, the majority of NCAM mRNA in postnatal skeletal
muscle was shown to contain extra exons inserted between exons
12 and 13. Of the various possible exon combinations at this
splice site, the combinations 12-a-AAG-1 3 and 12-a-b seemed to
be prevalent in postnatal skeletal muscle. No significant change
in the relative proportion of these two exon combinations
occurred during aging. The observed upregulation of NCAM
protein in aged muscle supports the assumption that an increasing
proportion of muscle fibres are denervated in aged muscle.
Selective upregulation of the 5.2 and 2.9 kb mRNA forms have
previously been demonstrated in muscle cell lines and in primary
cultures of muscle cells during formation of myotubes in vitro,
and this switch in NCAM mRNA classes has been suggested to
correlate with myogenesis. However, the selective upregulation
of the 5.2 and 2.9 kb mRNA classes is even more pronounced
after muscle denervation [Covault, Merlie, Goridis and Sanes
(1986) J. Cell Biol. 102, 731-739] as well as in the age-related
NCAM upregulation reported here. We therefore suggest that
upregulation of the 5.2 and 2.9 kb NCAM mRNA forms in
muscle may be correlated with lack ofinnervation of the myofibre
rather than to myogenesis per se.
INTRODUCTION
The neural cell adhesion molecule (NCAM), is a cell surface
glycoprotein which mediates cell-cell and cell-substratum bind-
ing [for review, see Linnemann and Bock (1989)]. NCAM-
mediated cell adhesion plays a role in several morphogenetic
events, including muscle formation and innervation (Rutishauser
et al., 1983; Knudsen et al., 1990; Dickson et al., 1990).
Involvement of NCAM in these processes is thought to depend
on temporal and spatial regulation of transcription, translation
and post-translational modulation of the molecule. Changes in
the surface density of NCAM have been shown to have a
pronounced effect on binding efficiency. Thus, a doubling of
NCAM concentration increases binding rates 30-fold (Hoffman
and Edelman, 1983). The carbohydrate structure of NCAM also
changes during development. Embryonic brain NCAM is heavily
glycosylated, with most of the carbohydrate moiety consisting of
polysialic acid residues with an average chain length of
approximately 25 sialic acids or more (Frelinger and Rutishauser,
1986). Later in development, NCAM polysialylation is reduced
(Linnemann et al., 1985). Even though polysialic acid residues do
not participate directly in NCAM binding, they diminish the
binding affinity of the molecule (Sadoul et al., 1983; Moran and
Bock, 1988).
NCAM is the product of a single-copy gene, which consists of
at least 25 exons (Owen et al., 1987; Small et al., 1987; Gower et
al., 1988; Thompson et al., 1989; Santoni et al., 1989). By
alternative splicing and polyadenylation, five NCAM mRNA
classes with sizes of 7.4, 6.7, 5.2, 4.3 and 2.9 kb are generated in
rodents (see Figure 1). Exons 1-14 seem to be expressed in all
NCAM mRNAs. Alternative usage of the 3'-end exons 15-19
produces mRNAs encoding three major NCAM polypeptide
species with different C-termini. In the 7.4 kb mRNA class,
exon 14 is followed by exons 16, 17, 18 and 19. This mRNA class
encodes a transmembrane NCAM species with a long cytoplasmic
domain. The 6.7 kb mRNA class contains exons 16, 17 and 19,
Abbreviations used: NCAM, neural cell adhesion molecule; PVDF, polyvinylidene difluoride; WB, washing buffer; GPI, glycosylphosphatidylinositol;
PI-PLC, phosphatidylinositol-specific phospholipase C; poly(A)+, polyadenylated; PMSF, phenylmethanesulphonyl fluoride.
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but lacks exons 15 and 18. As a result this mRNA class encodes
a transmembrane NCAM species with a relatively short cyto-
plasmic domain. Both the 5.2 and 2.9 kb mRNA classes contain
exons 1-15, but lack exons 16-19. These two mRNA classes are
both considered to encode an NCAM species that is attached to
the membrane via a glycosylphosphatidylinositol (GPI) anchor
(Owen et al., 1987; Barthels et al., 1987). The difference in size
between the 5.2 and the 2.9 kb mRNA classes is due to alternative
polyadenylation (Barbas et al., 1988). The protein product of the
4.3 kb mRNA has not yet been identified, but this mRNA class
has been shown to contain exons encoding intracellular sequences
(Small et al., 1987; Andersson et al., 1990). Evidence for yet
anotherNCAM polypeptide species comes from the identification
of a human NCAM cDNA clone, containing an alternatively
spliced exon termed SEC. SEC may be inserted between exons 12
and 13 and contains a stop codon 63 bp downstream. This means
that NCAM mRNA containing exon SEC encodes a truncated
NCAM species which lacks any membrane attachment, and
hence is a soluble NCAM species (Gower et al., 1988). However,
this secreted isoform has not been demonstrated in mouse muscle
by the PCR technique (Hamshere et al., 1991).
NCAM is a member of the Ig gene superfamily (Hemperly et
al., 1986; Cunningham et al., 1987). Members of this family all
share a common extracellular polypeptide domain called the Ig
homology unit [for a review, see Salzer and Colman (1989)]. Ig
homology domains have been divided into constant (C) and
variable (V) domains, which differ with regard to the number of
antiparallel f-strands (seven and nine respectively) and amino
acid sequence patterns around cysteine residues. NCAM and
other CAMs of the Ig superfamily contain homology units with
features intermediate between C and V domains. This domain
type is termed C2 (Williams and Barclay, 1988). NCAM contains
five C2 Ig homology domains, which constitute the N-terminal
part of the molecule (Hemperly et al., 1986). The cell-substratum
and cell-cell binding sites are presumed to be located in Ig
domains two and three respectively, and Ig domain five contains
the attachment site for polysialic acid-containing carbohydrate
chains (Frelinger and Rutishauser, 1986).
Alternative splicing is known to occur in Ig domain four. A
30 bp exon called VASE (variable-domain, alternatively spliced
exon) may be inserted between exons 7 and 8, which together
encode this Ig domain (Small et al., 1987; Small and Akeson,
1990). NCAM mRNA containing VASE is expressed in both
brain and heart, and VASE is present in all five NCAM mRNA
classes. The fraction of NCAM mRNA that contains VASE
increases with age from 3 % and 10% in embryonal day 15 brain
and heart respectively to approximately 50% in adult brain and
heart (Small et al., 1988; Small and Akeson, 1990; Andersson et
al., 1990; Reyes et al., 1991). Neural and muscle cell lines express
no or very little VASE (Small and Akeson, 1990). The functional
significance of the expression of VASE is not clear. Insertion of
the ten amino acids encoded by VASE changes Ig domain four
from a C2 to a more V-like Ig domain. Variable Ig domains are
involved in antigen binding, and it is tempting to assume that the
insertion of VASE-encoded sequences in Ig domain four may
introduce a binding site in this domain.
Another position of alternative splicing in the extracellular part
ofNCAM is located C-terminally to the Ig domains, close to the
transmembrane part of the molecule. At this site, which is
located between exons 12 and 13, a complex alternative splicing
pattern is displayed. Besides the above mentioned exon SEC,
four exons, designated a, b, c (formerly MSD la-c) and AAG of
respectively 15, 48, 42 and 3 bp, may be inserted here. When
present simultaneously, these four exons encode a presumed
1987). The MSD1 domain is predominantly contained in GPI-
anchored NCAM forms, and the joint expression of the four
exons is thus mainly associated with the 5.2 and 2.9 kb mRNA
classes [for a review, see Walsh and Dickson (1989)]. However,
other combinations of these four exons have been demonstrated
in muscle, heart and brain (Santoni et al., 1989; Andersson et al.,
1990; Reyes et al., 1991; Hamshere et al., 1991). The expression
of exons b and c is mainly restricted to skeletal and cardiac
muscle, whereas exons a and AAG are also expressed in brain
(Reyes et al., 1991). The significance of the variable polypeptide
sequences encoded by different combinations of these four exons
on NCAM function is still unknown. Their localization distant
from the suggested binding sites in the Ig domains may indicate
that they are only indirectly involved in intermolecular inter-_
action. Expression of exon a introduces a stretch of four
proline residues, which has been suggested to induce a flexible
'hinge' region into NCAM (Walsh and Dickson, 1989). Further-
more, expression of the MSD1 domain has been shown to
introduce an attachment site for 0-linked glycosylation in the
NCAM molecule (Walsh et al., 1989).
In embryonic muscle, NCAM is uniformly present on the
surface of myotubes, but, as the myotubes mature, NCAM is
downregulated and postnatally NCAM becomes concentrated in
synaptic regions (Covault and Sanes, 1986). However, after
denervation or during disease-associated muscle degeneration,
NCAM expression is again upregulated (Moore and Walsh,
1985; Covault et al., 1986; Cashman et al., 1987). NCAM in rat
skeletal muscle is known to be encoded by three 6.7, 5.2 and
2.9 kb mRNAs and expressed mainly as a transmembrane
140 kDa and a GPI-anchored 125 kDa NCAM polypeptide
(Covault et al., 1986; Moore et al., 1987). The 140 kDa NCAM
isoform is expressed throughout embryonic and postnatal de-
velopment, whereas the 125 kDa isoform is upregulated
perinatally (Covault et al., 1986). Alternative splicing of NCAM
mRNA at the exon 12-13 junction has been investigated in
mouse skeletal muscle using the PCR technique (Hamshere et al.,
1991) By this technique the exon combinations 12-13, 12-AAG-
13 and 12-a-b-c- 13 were found to be prevalent in NCAM mRNA
from adult muscle. The expression of VASE in normal skeletal-
muscle tissue has not previously been studied. neither has the
expression ofNCAM in aged rat skeletal muscle been described
before.
We here report a study on NCAM expression in aging skeletal
rat muscle. We observed that significant changes in NCAM
expression, both at the mRNA and protein level, occurred. In
aged muscle a considerable increase in NCAM occurred com-
pared with young adult muscle. Furthermore, selective up-
regulation of certain NCAM mRNA classes was observed.
MATERIALS AND METHODS
Tissue
Hindleg bulk muscle, brain and liver were dissected from
Wistar rats. Biopsies were obtained from Wistar rats at the
following ages: postnatal day 1 (P1), 10 (PIO), 40 (P40),
270 (P270, corresponding to a 9 month+ 10 day-old-rat), and 730
(P730, corresponding to a 24 month+ 10-day-old rat).
Oligonucleotides
Oligonucleotides (30-40 nt) specific for different NCAM mRNAs
were constructed using published sequences of NCAM cDNA
clones (see Figure 1). The following oligonucleotide probes were
constructed from the rat NCAM cDNA sequence published by
muscle-specific NCAM domain termed MSD1 (Dickson et al., Small et al. (1987); probe E7 covering nt 1187-1217, which
Neural cell adhesion molecule in aging rat skeletal muscle 643
hybridizes to part of exon 7 contained in all NCAM mRNA
classes; probe EVASE covering nt 1271-1300 and probe E7/8
covering nt 1257-1270+1301-1315, which are specific for
NCAM mRNA that either possesses or lacks VASE respectively;
probe E16 covering nt 2502-2541, which hybridizes to part of
exon 16. From the murine NCAM cDNA sequence published
by Santoni et al (1989), oligonucleotide probes specific for
exon a followed by AAG (probe E12/a/AAG/13, nt 1946-
1959 + a +AAG + 1960-1969) and mRNA lacking alterna-
tively spliced exons between exon 12 and 13 (probe E12/13,
nt 1946-1976) were constructed.
From the human NCAM cDNA sequence published by
Dickson et al. (1987) probe E12/a/b covering nt 316-347 was
constructed. This probe was expected to recognize mRNA
containing exon 12 followed by exons a and b. However, when
the sequences ofexons b and c in rat were subsequently published
(Reyes et al., 1991), it became apparent that this probe may also
recognize mRNA containing exons 12-a- 13 and to a lesser extent
exon 12-a-c. Oligonucleotides were synthesized on a Biosearch
8750 DNA synthesizer and labelled with [32P]dATP (New
England Nuclear) using a DNA-tailing kit from Boehringer-
Mannheim Biochemica. The specificity of the oligonucleotide
probes has previously been described in Andersson et al. (1990).
Northern-blot analysis
Northern-blot analysis was performed as described by Andersson
et al. (1990). In general, prehybridization (2 h) and hybridization
(18-20 h) were performed at 60-70 °C in a. solution containing
4 x SSC (1 x SSC = 0.15 M NaCl+0.015 M sodium citrate),
0.1 0% SDS, 0.1 0% Denhardt's solution [20% Denhardt's solu-
tion = 2% Ficoll+ 2% BSA + 2 % poly(vinylpyrrolidone)],
0.2 mM EDTA, 200 4ug poly(A)/ml, 0.06% tetrasodium diphos-
phate. After hybridization, filters were washed in 1 x SSC/0. 1 %
SDS at hybridization temperature. Results are based on three to
five independent RNA preparations of each age group.
An RNA standard from BRL was applied to every gel.
Poly(A)+RNA from brain and liver were used as positive and
negative controls respectively. The amount of poly(A)+RNA on
blots was evaluated by ethidium bromide staining.
Antibodies
Polyclonal rabbit anti-(rat brain NCAM) antibodies were pre-
pared as described by Rasmussen et al. (1982). For immuno-
blotting experiments, these antibodies were purified as follows:
brain membrane proteins from adult rats were submitted to
SDS/PAGE and electroblotted on to nitrocellulose paper
(Millipore Corporation) as described below. Bands containing
the 190 and 135 kDa NCAM isoforms were excised, blocked
with 20% Tween 20 (Sigma) and incubated with anti-NCAM
antibodies. The nitrocellulose was washed five times for 10 min
in washing buffer (WB) consisting of 50 mM Tris/HCl, pH 10.2,
150 mM NaCl, 0.1 mM phenylmethanesulphonyl fluoride
(PMSF) and 0.050% Tween 20. Bound antibodies were eluted
with a solution containing 0.1 M sodium citrate buffer, pH 2.6,
0.5 M NaCl, 1 % BSA and 0.05 % Tween 20 for 2 min. Eluted
antibodies were adjusted topH 10.2. From the same nitrocellulose
paper, other parts not containing NCAM were incubated with
anti-NCAM antibodies and treated as described above. These
eluates were used as control antibodies.
The monoclonal mouse antibody OBi 1 was a generous gift
directed against a cytoplasmic epitope common to the rat 190
and 135 kDa NCAM isoforms in brain (Neill and Barnstable,
1990). All other antibodies used were obtained from Dakopatts.
Immunoblotting
Total muscle homogenates contain a substantial amount of
myosin which interferes with electrophoresis and may give rise to
unspecific binding of antibodies in immunoblotting. In order to
reduce this technical problem, muscle tissue was fractionated as
follows. Muscle tissue was homogenized in 50 mM Tris/HCl,
pH 7.4, 15 mM NaN3 and centrifuged at 18000 g for 15 min. The
supernatant was subsequently centrifuged for 1.5 h at 100000 g
to produce a high-speed supernatant. The membrane fraction
was solubilized by sonication in a Triton-solubilization buffer
(TB) consisting of 20% Triton X-100, 15mM NaN3, 10mM
Tris/barbital buffer, pH 8.6, and 100 units/ml aprotinin (Bayer)
followed by centrifugation for 15 min at 18000 g to produce a
Triton X-100-soluble membrane fraction. The Triton X-100-
insoluble fraction was subsequently washed three times in TB.
All fractions (high-speed superantant, TB-soluble membrane
fraction, TB washing fractions and the TB-insoluble membrane
fraction) were boiled in SDS/PAGE sample buffer containing
5% 2-mercaptoethanol and applied to 7.5 % gels essentially as
described by Laemmli (1970).
Separated proteins were electroblotted on to a polyvinylidene
difluoride (PVDF) membrane (Millipore Corporation). Non-
specific binding was blocked by incubation with 2 % Tween 20 in
WB (see above). Primary antibodies were diluted in WB. Alkaline
phosphatase-conjugated swine anti-rabbit immunoglobulin was
used as secondary antibody. Results are based on a minimum of
four rats in each age group. The three major NCAM isoforms
from adult rat brain of 190, 135 and 115 kDa were used as
molecular-mass markers.
When incubation with OB 11 was carried out, it was necessary
to immunopurify NCAM before SDS/PAGE. CNBr-activated
Sepharose 4B beads (Pharmacia) were coupled to polyclonal
rabbit anti-(rat NCAM) antibodies as described by the manu-
facturer. Solubilized proteins were incubated with antibody-
coupled beads for 30 min at 4 'C. Beads were subsequently
washed twice in PBS, once in PBS containing 0.1 M NaCl and
finally in 10 mM Tris/barbital buffer, pH 8.6. Beads containing
bound NCAM were boiled in SDS/PAGE sample buffer and,
after centrifugation at 18 000 g for 5 min, supernatant now
containing NCAM was subjected to SDS/PAGE as specified
above. After electrotransfer to a PVDF membrane, non-specific
binding was blocked in PBS containing 10 mM NaCl and 2%
BSA. OBi washing buffer consisted of PBS with 0.1 0% BSA,
and the antibody was diluted in PBS containing 2% BSA and
15 mM NaN3. Alkaline phosphatase-conjugated rabbit anti-
mouse immunoglobulin was used as secondary antibody.
Enzyme treatment
Endosialidase N was a generous gift from Dr. Jurgen Roth,
University of Basel. For endosialidase N treatment, membrane
fraction or high-speed supernatant was mixed with 4 x 101 units
of endosialidase N/ml of sample (10" units/ml digests 100 jug of
polysialic acid after 24 h at 37 'C) and incubated for 30 min at
37 'C. Control samples were incubated without enzyme for
30 min at 37 'C or at 4 'C. As a control for enzyme activity,
polysialylated samples from newborn brain were treated with
endosialidase N and analysed by immunoblotting, converting
from Dr. Harry Langbeheim, Biomakor, Israel. This antibody is diffuse polysialyated zones into distinct desialylated bands.
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E.I.i.s.a.
Quantification of NCAM was performed by an e.l.i.s.a. as
described by Ibsen et al. (1983). Tissues were homogenized in
70 mM Tris/barbital buffer, pH 8.6, containing 1 % Triton X-
100, 0.1 mM PMSF and 15 mM NaN3. Quadruplicate determin-
ations were performed on four rats in each age group. Total
protein was determined by the method of Lowry et al. (1951).
Differences in NCAM amount were statistically tested by
Student's t test. 2P < 0.05 were considered to be statistically
significant.
RESULTS
NCAM mRNA expression in aging skeletal muscle
The NCAM mRNA expression in skeletal muscle during aging
was examined by Northern-blot analysis with various DNA
oligonucleotide probes. The probes were designed to specifically
recognize certain exons or exon combinations (Figure 1). Probe
E7 was used as a general NCAM probe. Using this probe,
hybridization to three NCAM mRNA classes of 6.7, 5.2 and
2.9 kb was observed in skeletal muscle (Figure 2a). All three
mRNA classes were expressed from postnatal day 1 (P1) to 40
(P40) (Figure 2a, lanes 2-4). At P1 and PlO, the three NCAM
mRNAs were abundant and present in approximately equal
amounts (Figure 2a, lanes 2 and 3). In P40 muscle, the total
NCAM mRNA amount was greatly decreased and at this age the
5.2 and 2.9 kb mRNAs were slightly more abundant than the
6.7 kb mRNA (Figure 2a, lane 4). In P270 (9 months old)
muscle, NCAM mRNA was hardly detectable, whereas in P730
(24 months old) muscle, the 5.2 and 2.9 NCAM mRNA classes
were upregulated and clearly expressed (Figure 2a, lanes 5 and
6). The 6.7 kb mRNA was not upregulated and hardly detectable
at this age (lane 6). Thus, during aging, not only the total NCAM
mRNA amount but also the expression of individual mRNA
classes changed.
Hybridization with probe E16 was performed in order to
determine which NCAM mRNAs in skeletal muscle encode
transmembrane NCAM forms. This probe is complementary to
part of exon 16, which encodes transmembrane and cytoplasmic
regions of NCAM. Probe E16 specifically hybridized to the
6.7 kb mRNA in skeletal muscle (for PlO, see Figure 2b, lane 2).
Thus translational potential for both transmembrane and GPI-
anchored NCAM species was present in perinatal and young
adult muscle, whereas in aged muscle mainly mRNAs encoding
GPI-anchored NCAM species could be demonstrated by this
technique.
Expression of VASE In skeletal-muscle NCAM mRNA
The alternative splicing between exon 7 and 8 in skeletal-muscle
NCAM mRNA was studied using probes E7/8 and EVASE.
Probe E7/8 only hybridizes to NCAM mRNAs that lack
alternatively spliced sequences inserted between exons 7 and 8.
Probe EVASE, on the other hand, is complementary to VASE.
The majority of NCAM mRNAs in skeletal muscle lacked
alternative splicing between exon 7 and 8 at all ages examined
(compare Figures 3a and 3b). Using probe EVASE, only barely
detectable levels ofVASE could be observed in the 5.2 and 2.9 kb
NCAM mRNA in perinatal as well as aged muscle after
prolonged exposure times (Figure 3b, lanes 2 and 3). Compared
with the expression of VASE in adult brain (Figure 3b, lane 1)
the expression in skeletal muscle was negligible.
Alternative splicing between exon 12 and 13 in skeletal-muscle
NCAM mRNA
Several combinations of the a, b, c, AAG and SEC exons may be
inserted between exons 12 and 13 (Dickson et al., 1987; Santoni
E7 E7/8 E12/13
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Figure 1 Schematic presentation of the known NCAM exons
Exons common to all NCAM species are white. Exons common to transmembrane NCAM
species are light grey, whereas the exon specific for the largest transmembrane NCAM isoform
is hatched (n). The black exon is specific for mRNA encoding GPI-anchored NCAM isoforms.
Alternately spliced exons encoding extracellular sequences are striped. The approximate
localization of the employed oligonucleotide probes (see the Materials and methods section) is
indicated by solid lines. All exons on the figure are of equal size. In reality the sizes vary
considerably. Insert: Diagram of the three major polypeptide species encoded by NCAM
mRNAs, and their association with the cell membrane. White, light-grey and hatched regions
are encoded by exons with the corresponding signature. The black segment represents the GPI
anchor. The sequence encoded by exon 15 constitutes a signal sequence for GPI linkage, which
is presumed to be removed on attachment of the GPI anchor. Hence, the exon 15-encoded
sequence is presumably not present in mature GPI-anchored NCAM isoforms (He et al., 1987).
Dotted vertical lines represent the two sites of alternate RNA splicing in the extracellular part
of NCAM. *, Exon 7-exon 8 splice site; +, Exon 12-exon 13 splice site.
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Figure 2 Northern-blot analysis of NCAM mRNA expression in normal rat
skeletal muscle during aging.
In (a) the general NCAM probe, E7, was hybridized to poly(A)+RNA from adult brain (lane 1),
postnatal day (P) 1 muscle (lane 2), P10 muscle (lane 3), P40 muscle (lane 4), P279 muscle
(lane 5) and P730 muscle (lane 6). Lanes 2-6 were from the same autoradiogram. In (b), probe
El16 specific for mRNA encoding transmembrane NCAM species was hybridized to adult brain
(lane 1) and PlO0 muscle (lane 2). Lane 1 in both (a) and (b) contained 10 /4ug of poly(A)+RNA
and all other lanes contained 15 4ug of poly(A)+RNA. The sizes of the hybridizing species are
indicated on the left hand side (kb), In (a), the positions of standards are indicated on the right
hand side.
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Figure 3 Northern-blot analysis of splicing of NCAM mRNA at the
exon 7-oxon 8 junction in normal rat skeletal muscle
In (a), probe E7/8 was hybridized to adult brain (lane 1), postnatal day (P) 1 muscle (lane 2),
P10 muscle (lane 3), P40 muscle (lane 4), P270 muscle (lane 5) and P730 muscle (lane 6).
All lanes were from the same autoradiogram. In (b), probe EVASE was hybridized to adult brain
(lane 1), P1 muscle (lane 2) and P730 muscle (lane 3). Lanes 1 and 2 were from the same
autoradiogram, lane 3 was from a comparable autoradiogram. Lane 1 in both (a) and (b)
contained 10 ,ug of poly(A)+RNA and all other lanes contained 15 1g of poly(A)+RNA. The
sizes of the hybridizing species are indicated on the left hand side in (kb). The positions of RNA
standards are indicated on the right hand side in (a).
et al., 1989; Andersson et al., 1990; Reyes et al., 1991). Collective
expression of exon a, b, c and AAG is believed to be restricted
to the 5.2 and 2.9 kb mRNA classes in muscle. However, little is
known about the distribution of other combinations of these
exons in the 6.7, 5.2 and 2.9 kb mRNA classes or about the
frequency of alternative splicing at this site in muscle mRNAs.
By means of probes E12/13, E12/a/AAG/13 and E12/a/b, we
examined the prevalence of alternative splicing between exons 12
and 13 in normal skeletal muscle and attempted to relate the
expression of some possible exon combinations to the different
NCAM mRNA classes. According to the nomenclature of the
probes, probe E12/13 recognizes NCAM mRNA lacking
alternatively inserted sequences between exons 12 and 13, probe
E12/a/AAG/13 recognizes NCAM mRNA containing exons a
and AAG inserted between exons 12 and 13 and probe E12/a/b
recognizes NCAM mRNA containing exon 12 followed by exons
a and b, with the reservations mentioned in the Materials and
methods section.
In all threemRNA classes, expression ofbothNCAM mRNAs
containing and lacking inserted exons between exons 12 and 13
Figure 4 Northern-blot analysis of splicing of NCAM mRNA at the
exon 12-exon 13 junction in normal rat skeletal muscle
In (a), probe El 2/13 is hybridized to adult brain (lane 1), postnatal day (P) 10 muscle (lane 2)
and P730 muscle (lane 3). Lanes 1 and 3 were from the same autoradiogram, lane 2 was from
a comparable autoradiogram. Hybridization of probe E12/a/AAG/13 and E12/a/b is shown in
(b) and (c) respectively. Lane 1, adult brain; lane 2, P1 muscle; lane 3, P10 muscle; lane 4,
P40 muscle; lane 5, P270 muscle; lane 6, P730 muscle. All lanes were from the same
autoradiogram. Lane 1 contained 10 ,ug of poly(A)+RNA and all other lanes contained 15 ,ug
of poly(A)+RNA. The sizes of the hybridizing species are indicated on the left hand side (kb).
was observed (Figure 4a-4c). The 6.7 kb mRNA class in muscle
consisted mainly ofmRNA lacking alternative splicing between
exons 12 and 13. Hybridization to this mRNA class could,
however, be faintly observed with both probes E12/a/AAG/13
and E12/a/b with prolonged exposure (not shown). The 5.2 and
2.9 kb mRNA classes consisted mainly of mRNA isoforms
containing additional exons between exons 12 and 13 (Figure 4b
and 4c). The fraction of NCAM mRNA containing alternative
splicing between exons 12 and 13 in skeletal muscle did not seem
to change significantly compared with total NCAM mRNA
during aging (compare Figure 2a and Figure 4b and 4c).
Hybridization with probe E12/a/AAG/13 showed that
expression of the exon combination 12-a-AAG-13, which has
previously been demonstrated in brain and heart (Andersson et
al., 1990; Reyes et al., 1991), also occurs in postnatal skeletal-
muscle NCAM (Figure 4b). This indicates that the expression of
exon a in skeletal muscle, as well as in brain and heart, is
regulated independently of exons b and c. Indeed, this exon
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Table 1 Exons and exon combinations demonstrated in adult and aged rat
skeletal muscle by Northern-blot analysis
Parentheses indicate a weak reaction not seen in all experiments.
mRNA 12/al
classes 7 7/8 VASE 12/13 AAG/1 3 12/a/b 16
6.7 kb + + - + (+) (+) +
5.2 kb + + (+) + + + -
2.9 kb + + (+) + + + -
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Figure 5 Immunobloftlng of NCAM isoforms expressed in normal rat
skeletal muscle during aging
Muscle membranes from postnatal day (P) 1 (lanes 1 and 4), P10 (lanes 2 and 5), P40 (lanes
3 and 6), P270 (lane 7), P730 (lane 8), muscle high-speed supernatant from P1 (lane 9),
immunopuritied NCAM (see the Materials and methods section) from P1 muscle (lane 10) and
P40 rat brain (lane 11). Samples in lanes 1-3 were treated with endosialidase N (+N).
Samples in lanes 4-11 were untreated (-N). Lanes 1-9 were incubated with retroblotted
polyclonal NCAM antibodies. Lanes 10 ard 11 were incubated with the monoclonal antibody
OB1 1, which reacts with an epitope on the cytoplasmic domain of NCAM. Lanes 1-5 were run
on the same gel, lanes 7-9 and 10 and 11 likewise. In all experiments, newborn muscle
membranes and P40 brain membranes served as internal controls. Total protein applied per lane
was 13 ,ug (lanes 1-5, 7 and 8), 60 ,ug (lane 6) and 110 ,ug (lane 9). The positions of the
three major 190, 135 and 115 kDa NCAM isoforms from P40 rat brain are indicated on the
left-hand side.
encoding GPI-anchored NCAM isoforms in substantial amount.
Hybridization with probe E12/a/b showed that the exon com-
bination 12-a-b was also substantially expressed in muscle mRNA
encoding GPI-anchored NCAM (Figure 4c). Hybridization
signals obtained using probe E12/a/b possibly consisted of
various NCAM mRNAs with exon b followed by different exons
such as, e.g., exon c, exon AAG or exon 13.
The hybridization results are summarized in Table 1.
NCAM polypeptide composition in aging skeletal muscle
NCAM protein expression was examined in skeletal muscle from
P1, PlO, P40, P270 and P730 rats by immunoblotting using
retroblotted polyclonal anti-NCAM antibodies that recognize all
NCAM isoforms. Tissue homogenates were separated into a
buffer-soluble high-speed supernatant, a Triton X-100-soluble
membrane fraction and a Triton X-100-insoluble membrane
fraction as described in the Materials and methods section.
In the Triton X-100-soluble skeletal-muscle membrane frac-
tion, four polypeptides of 200, 145, 125 and 120 kDa were
observed at all ages investigated, with the 145 kDa polypeptide
being predominant (Figure 5, lanes 4-8). Occasionally a 165 kDa
polypeptide was also observed. Control antibodies did not react
with NCAM polypeptides. Expression of NCAM polypeptides
decreased during postnatal life to a very low level in P40 muscle
(Figure 5, lanes 1-3). In aged muscle the level of NCAM
polypeptides had increased (Figure 5, lanes 3 and 6-8, note that
the amount of applied protein is higher in lane 6 than in the other
lanes). In early postnatal muscle, diffuse staining extended above
the 200 and 145 kDa bands and above the 120-125 kDa area. In
embryonal and early postnatal brain this pattern is known to be
caused by the presence of heterogeneously polysialylated NCAM
polypeptides (Finne et al., 1983; Linnemann et al., 1985). In
order to investigate whether this was also the case in skeletal
muscle, membranes of P1, PlO and P40 muscles were treated
with endosialidase N which removes polysialic acid residues. The
enzyme treatment removed the diffuse staining leaving only well-
defined bands (Figure 5, lanes 1-3). In contrast, controls
incubated without enzyme at either 4 °C or 37 °C were unchanged
(not shown). This indicated that NCAM expressed in early
postnatal skeletal muscle contained polysialic acid. At older ages
no diffuse staining was observed, indicating that no or only
minor polysialylation of NCAM occurred in young adult and
aged skeletal muscle.
Transmembrane NCAM polypeptides were identified using
the monoclonal antibody OB 11 which reacts with a cytoplasmic
epitope common to the transmembrane 190 and 135 kDa brain
NCAM isoforms (Figure 5, lane 11). Immunoisolated NCAM
polypeptides from skeletal-muscle membranes of 200 and
145 kDa reacted with OB 11 (Figure 5, lane 10), indicating that
these two polypeptides were carrying the cytoplasmic OB 11
epitope.
In order to study the expression ofsoluble NCAM polypeptides
in muscle, a high-speed supernatant was prepared from the
buffer-soluble fraction and analysed by immunoblotting. Soluble
NCAM polypeptides of 200, 145, 125 and 120 kDa comparable
in size with the polypeptides observed in the Triton X-100-
soluble membrane fraction were observed at all ages examined
[Figure 5, lane 9; only one age (P1) is shown]. The pattern of
soluble NCAM polypeptides did not seem to change during
aging (not shown). Diffuse staining was observed extending
above the NCAM polypeptide bands in the high-speed super-
natant at early postnatal ages. Treatment with endosialidase N
removed this diffuse staining, indicating that soluble NCAM
polypeptides also contained heterogeneous polysialylation at
these ages (not shown).
In the Triton X-100-insoluble fraction, NCAM polypeptides
of 145, 125 and 120 kDa were observed (not shown). In addition,
a large smear at approx. 200 kDa, presumably representing
unspecific binding to myosin, was observed. The relative amount
of the 145, 125 and 120 kDa polypeptides was apparently the
same as in the Triton X-100-soluble fraction. The ratio of the
amount ofNCAM in the membrane fractions to that in the high-
speed supernatant seemed to remain constant at all ages
investigated.
Amount of NCAM in aging skeletal muscle
The amount of total NCAM protein in P1, PlO, P40, P270 and
P730 skeletal muscle was determined using an e.l.i.s.a. (Figure 6).
Skeletal muscle at P1 contained 1.21 + 0.44 ,ug ofNCAM/mg of
total protein (mean + S.E.M., n = 4). The amount of NCAM
decreased to a minimum of 0.063 + 0.008 ,ag/mg of total protein
(n = 4) around P40. In aged muscle the NCAM amount increased
again to 0.37 + 0.11 ,ug/mg of total protein (n = 4) in P730 rats.
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Figure 6 Amount of NCAM in normal rat skeletal muscle determined by
e.i.i.s.a. and expressed as pg/mg of total protein
The age is indicated in days (270 days = 9 months, 730 days = 24 months). Values are given
as means+S.E.M. (n= 4).
The level of NCAM in P730 muscle was statistically significantly
higher than the level in P40 and P270 muscle (2P < 0.05).
DISCUSSION
NCAM mRNA expression in rat skeletal muscle
The data presented here show that significant changes in the
NCAM mRNA pattern occur in skeletal muscle during aging.
Thus three NCAM mRNAs of 6.7, 5.2 and 2.9 kb were expressed
during early postnatal development, being downregulated in
young adult muscle. In aged skeletal muscle the 5.2 and 2.9 kb
NCAM mRNAs were specifically upregulated, whereas the 6.7 kb
mRNA remained unchanged.
The exon VASE was found to be virtually absent from
postnatal skeletal muscle at all ages. In contrast, VASE is
expressed in both brain and heart in increasing amounts during
postnatal development (Small et al., 1988; Andersson et al.,
1990; Small and Akeson, 1990; Reyes et al., 1991). Thus
expression of NCAM isoforms containing the VASE-encoded
domain is not only developmentally regulated but also regulated
in a tissue-specific manner.
A major fraction of the 5.2 and 2.9 kb NCAM mRNAs was
shown to contain various combinations of exons inserted at the
exon 12-13 junction, whereas only a relatively small proportion
of the 6.7 kb mRNA contained inserted exons at this site. The
exon combinations 12-a-AAG-1 3 and 12-a-b were both found to
be abundant in postnatal skeletal muscle at all ages studied. No
change in the relative proportion of NCAM mRNA lacking or
containing extra exons inserted at the exon 12-13 junction
seemed to occur during aging (compare Figures 2a and 4b and
4c). The significance of these various exon combinations for
NCAM function remains to be clarified. We found that the
majority of NCAM mRNAs contained exons inserted between
exons 12 and 13 in adult and aged muscle, whereas Hamshere
and co-workers (1991) found that the exon combination 12-13
was the prevalent mRNA form. Moreover, these authors found
that the exon combination 12-a-AAG-13 was not expressed in
normal muscle and only expressed at a low level in the muscle cell
line C2, whereas we observed substantial amounts of this exon
combination in NCAM mRNA from muscle. This discrepancy
may be due to species differences or different techniques
employed.
Expression of NCAM protein in aging skeletal muscle
In agreement with previous observations (Rieger et al., 1985;
Covault et al., 1986), we observed a downregulation of NCAM
during early postnatal development to a very low level in young
adult skeletal muscle. However, in aged rat, muscle NCAM
protein level increased considerably. NCAM protein concen-
tration in aged skeletal muscle reached a level corresponding to
that previously reported for denervated rat muscle by Covault et
al. (1986). It has been suggested that a slow on-going
denervation-reinnervation process takes place in muscle
throughout life (Wernig and Dorlochter, 1989). In histo-
pathological studies of aged striated muscles, alterations
indicating a process of deterioration of both myogenic and
neurogenic origin have been observed, the neurogenic type being
predominant (Tomonaga, 1977). Furthermore, aged muscle and
denervated young muscle exhibit similar changes in myofibrillar
properties (Ansved and Larsson, 1989). During aging, the number
of muscle fibres and motor units decreases in rodent and man
(Caccia et al., 1979; Edstrom and Larsson, 1987). It has been
suggested that the decreased number of muscle fibres is due to
loss of entire motor units and incomplete reinnervation of
denervated muscle fibres by the remaining motor neurons (Caccia
et al., 1979; Edstr6m and Larsson, 1987) resulting from impaired
axonal regeneration in the aged rat (Drahota and Gutmann,
1961). The increased levels of NCAM in aged skeletal muscle
reported here support this assumption.
Although the proportions of the different NCAM mRNA
classes changed during aging, no apparent change in the pro-
portion ofNCAM polypeptides occurred. The increased amount
of the 145 kDa transmembrane NCAM form in aged muscle as
compared with that in young adult muscle was not accompanied
by an increase in the 6.7 kb mRNA class. This may imply that
the catabolism of the 145 kDa polypeptide is decreased in aged
muscle or, alternatively, that the translational rate of the 6.7 kb
mRNA is enhanced compared with the 5.2 and 2.9 kb mRNA
classes. The 145 kDa polypeptide was the predominant NCAM
isoform observed at all ages examined. Antibodies against
a cytoplasmic epitope of NCAM showed that both the 200
and 145 kDa polypeptides in muscle membranes were trans-
membrane NCAM isoforms, indicating that the 200 kDa
NCAM polypeptide is the muscle homologue to the
190 kDa NCAM polypeptide observed in brain. A 180 kDa
NCAM polypeptide presumably corresponding to the 200 kDa
polypeptide observed in this study has recently been observed in
primary cultures of mouse muscle cells (Tassin et al., 1991).
Failure to detect the 7.4 kb mRNA class encoding this NCAM
polypeptide in muscle at any age may be attributed to a very low
amount of this mRNA class, indicating either a low catabolism
of the 200 kDa NCAM polypeptide or an enhanced translational
rate of this mRNA class in muscle. Postnatal developmental
changes in the amount of the 200 kDa NCAM polypeptide
correlated with developmental changes in the total amount
of NCAM in muscle, indicating that expression of the 200 kDa
NCAM polypeptide is subject to the same regulation as the
other NCAM isoforms in skeletal muscle and thus may be
expressed by the same cells.
The 120-125 kDa NCAM isoform observed in this study in
the buffer-soluble fraction of muscle homogenate may be a GPI-
anchored NCAM isoform, spontaneously released from the
membrane. It has been demonstrated that a 125 kDa NCAM
polypeptide can be released from the surface of myotubes in
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primary culture when treated with phosphatidylinositol-specific
phospholipase C (PI-PLC) (Moore et al., 1987; Tassin et al.,
1991). GPI-anchored NCAM isoforms are also spontaneously
released from the membrane of C6 cells and muscle cells in
primary cultures (He et al., 1987; Tassin et al., 1991). An
additional PI-PLC-sensitive 155 kDa NCAM polypeptide has
been described in the mouse muscle cell lines C8-1 and C2 by
Moore et al. (1987). In this study neither a membrane-associated
nor a soluble 155 kDa polypeptide could be demonstrated.
Neither was this 155 kDa NCAM isoform observed in primary
cultures of mouse muscle cells by Tassin et al. (1991). The origin
of the soluble NCAM polypeptides of 200 and 145 kDa observed
in this study is uncertain. Soluble NCAM isoforms of similar size
have been demonstrated in rat brain and cerebrospinal fluid
(Krog et al., 1992).
Previous studies on rodent muscle expression of NCAM
polypeptide isoforms have given conflicting results. In normal
postnatal skeletal muscle, a major NCAM isoform of
140/145 kDa is generally observed (Rieger et al., 1985; Covault
et al., 1986; Daniloffet al., 1986). In contrast, a 125 kDa NCAM
polypeptide seems to predominate in postfusion muscle cell lines
and in primary cultures of myotubes (Covault et al., 1986;
Moore et al., 1987). These muscle cell cultures lack neuronal
stimulation. Since previous studies on denervated and paralysed
muscle have shown that neuronal stimulation regulates the level
of NCAM expression in skeletal muscle (Covault and Sanes,
1985; Moore and Walsh, 1986), we suggest that neuronal
stimulation may also regulate expression of individual NCAM
isoforms. Thus, the discrepancy between the major NCAM
isoforms observed in normal postnatal skeletal muscle tissue and
in in vitro systems lacking innervation may be due to the fact that
myotubes express different NCAM isoforms depending on their
state ofinnervation, indicating that the different NCAM isoforms
in muscle serve different functions.
Currently, new tools for the investigation ofindividual NCAM
isoforms are being produced. Thus, the availability of isoform-
specific antibodies and NCAM cDNA clones containing different
combinations of alternately spliced exons will enable further
studies of the distribution and function of specific NCAM iso-
forms. As more is learned about the role of individual NCAM
isoforms in muscle development and muscle-nerve interaction,
elucidation of changes in muscle NCAM expression during aging
may contribute to an increased understanding of the aging
processes in muscle.
Note added in proof (Received 18 December 1992)
Recently, a paper describing increased NCAM expression in
aging murine muscle has been published by Kobayashi et al.
(1992).
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